On December 11, 2019 NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, reported new breast cancer research findings presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) (Press release, NantHealth, DEC 11, 2019, View Source [SID1234552276]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Symposium, held at the Henry B. Gonzalez Convention Center in San Antonio, TX from December 10-14, provides state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
NantHealth’s presentation examined how results of the phase 3 KATHERINE clinical trial, first presented at SABCS 2018 and simultaneously published in the New England Journal of Medicine (NEJM), affected treatment patterns and regimen selections among general medical oncologists in the U.S. before and after the results were publicly released. Data from NantHealth’s Eviti Connect, an evidence-based treatment intelligence and web-based oncology decision support platform, was analyzed to determine the rate of requests for treatment authorization for adjuvant Ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive early-stage breast cancer.
Study results indicated an immediate increase in T-DM1 use in the months following SABCS 2018. Based on data pulled from Eviti Connect, 95 cases would have received adjuvant T-DM1 in Q1 2019 after 0 in Q4 2018. When comparing T-DM1 and Trastuzumab use in the adjuvant breast cancer setting for HER2-positive patients, T-DM1 use since December 2018 increased and Trastuzumab use decreased as a percentage of treatment plan requests for adjuvant HER2-positive patients.
"Our research clearly shows that presenting clinical data at a leading conference like the San Antonio Breast Cancer Symposium, and having the data simultaneously published in a medical journal, influences a broad audience of oncologists," said Sandeep "Bobby" Reddy, MD, Chief Medical Officer, NantHealth. "As results indicate an immediate increase in T-DM1 use in the months following SABCS 2018, leveraging multiple communications platforms is an important and effective way to relay practice-changing clinical data to practicing oncologists in the U.S. These forums and supporting scientific journals expose researchers, academics and medical professionals to the latest studies and ideas in the field for which they can apply to their practice."
Title: "Real world data on treatment patterns before and after reporting of the KATHERINE trial: a phase 3 study of adjuvant Ado-trastuzumab emtansine (T-DM1) versus trastuzumab in early stage HER2+ breast cancer"
Authors: Neil Margolis Ph.D., Vlad Kozlovsky, William A. Flood MD, Sandeep K. Reddy MD
Poster Session and Number: Session 1, P1-15-08
Location: Henry B. Gonzalez Convention Center
Date and Time: Wednesday, December 11, 2019 (5:00 PM – 7:00 PM CT)
"As cancer therapies become more complex, Eviti was designed to help oncologists validate cancer treatment options and align all parties around value-based oncological care. Defining the appropriate regimens for patients is essential, and studies like this are an effective way to communicate how medical meetings and peer-reviewed journals are a valuable and timely way to get information to physicians," said Dr. William A. Flood, CMO of Eviti.